Coherus Oncology, Inc.

Direct answer

Coherus Oncology, Inc. is publicly traded on NASDAQ under the ticker CHRS.

Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory...

Can you invest in Coherus Oncology, Inc.?

Yes. Coherus Oncology, Inc. is publicly traded on NASDAQ under the ticker CHRS.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Coherus Oncology, Inc.

Detailed equity research is provided by MarketSnap.